Top Markets
#1 Black Phoenix Black Phoenix +736.78%
#2 Beam Beam +33.31%
#3 SAFEcoin SAFEcoin +19.80%
#4 THORChain THORChain +18.15%
#5 Tutorial Tutorial +17.03%
#6 Bless Bless +15.48%
#7 TENDIES TENDIES +15.42%
#8 EfficientFrontier EfficientFrontier +15.28%
#9 THORChain Yield THORChain Yield +13.62%
#10 Versatize Coin Versatize Coin +12.49%
Coin of the day
Black Phoenix Black Phoenix
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
RayzeBio, Inc. Common Stock RayzeBio, Inc. Common Stock

RayzeBio, Inc. Common Stock

RYZB
Rang in Aktien #5675
RayzeBio, Inc. is dedicated to creating radiopharmaceutical therapies (RPTs)... RayzeBio, Inc. is dedicated to creating radiopharmaceutical therapies (RPTs) for oncology applications. Its primary therapeutic candidate, RYZ101, is currently advancing through Phase 3 clinical trials for the management of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The company's innovative pipeline also features RYZ801, a distinct peptide engineered to deliver Actinium-225 (Ac225) by targeting GPC3, intended for treating hepatocellular carcinoma (HCC). Additionally, RayzeBio is developing RYZ811, a companion diagnostic imaging agent comprising a peptide binder, a chelator, and Gallium-68 (Ga68). Another active development program involves a novel proprietary small molecule designed to target CA9, delivering Ac225 for potential use against clear cell renal cell carcinoma (ccRCC). The firm was established in 2020 and is headquartered in San Diego, California.
Aktienkurs
$62.49
Zuletzt synchronisiert: 2024-03-06
Marktkapitalisierung
$2.52B
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
US
Handel RayzeBio, Inc. Common Stock (RYZB)

Kategorie

Healthcare
P/S-Verhältnis für RayzeBio, Inc. Common Stock (RYZB)
P/S-Verhältnis zum 2026 TTM: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von RayzeBio, Inc. Common Stock beträgt das aktuelle Kurs-Umsatz-Verhältnis (TTM) 0. Am Ende des Jahres 2026 lag das P/S-Verhältnis bei 0.
P/S-Verlauf für RayzeBio, Inc. Common Stock von 2026 bis 2026
P/S-Verhältnis zum Jahresende
Jahr P/S-Verhältnis ändert
Nicht genügend Daten für die angegebenen Daten.
P/S-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/S-Verhältnis P/S-Verhältnis-Differenz Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.17 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.13 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
11.28 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
2.95 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH